Table 1 Main characteristics of the four COVID-19 vaccines approved in Europe as of July 28, 2021
Developer | Commercial name | Type | Number of doses | Dosage interval |
|---|---|---|---|---|
Pfizer–BioNTech | Comirnaty | mRNA-based | 2 | 3–12 weeks |
Moderna | COVID-19 Vaccine Moderna | mRNA-based | 2 | 4 weeks |
AstraZeneca | Vaxzevria | Adenovirus vector-based | 2 | 4–12 weeks |
Johnson and Johnson - Janssen Pharmaceuticals | COVID-19 Vaccine Janssen | Adenovirus vector-based | 1 | – |